Meredith Gunder, MD, MS

Surgical Oncologist at @InovaSchar 🦈 by way of @UofLDeptofSurg #CGSO and @TempleSurgery residency 😷🔪💉 @DukeAlumni '13 💙😈🏀 dog mom 🐕

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Syed A. Ahmad @SyedAAhmad5]

True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm @annsurgoncol https://t.co/LNmqncPScr

[Syed A. Ahmad @SyedAAhmad5]

FDA grants early access to pancreatic cancer drug daraxonrasib https://t.co/6fzyUlnaEA

[Arndt Vogel @ArndtVogel]

DNA/RNA-Based NGS Improves the Early Diagnosis and Management of Neoplastic Bile Duct Strictures: A 6yr, Prospective, Multi-Institutional, Real-Time Study
@AGA_Gastro
https://t.co/JGvztO7QXt
👏Impressive and timely study
👉DNA/RNA- NGS from brushings, biopsies & bile is very useful
@myESMO @ASCO @ILCAnews @EASLedu

[NCAA March Madness @MarchMadnessMBB]

On this day in 1992, Christian Laettner hit The Shot for Duke 🤩

A #MarchMadness moment we'll never forget 🙌

[The New York Times @nytimes]

From @TheAthletic: For 40 years, Duke has been college basketball’s most polarizing team. People love to hate Duke.

But has Duke basketball become less hateable? Perhaps, maybe, even likable? https://t.co/Z2jcL2ANjA

[Meredith Gunder, MD, MS @MeredithGunder]

Biology is king

[Syed A. Ahmad @SyedAAhmad5]

Not surprised by results.
👇🏼👇🏼

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial ⁦@JAMAOnc⁩ https://t.co/ieUiKWApDD

[Meredith Gunder, MD, MS @MeredithGunder]

Same-Day Multidisciplinary Clinics for Patients With Newly Diagnosed Adult Solid Tumor Cancer: A Systematic Review | JCO Oncology Practice https://t.co/OhgV5Zys7e @InovaSchar

[Annals of Surgical Oncology @AnnSurgOncol]

#AudioVisualAbstract : The Relationship Between Area-Level #Marginalization and Overall Survival of Patients with Soft Tissue #Sarcoma in Ontario: A Retrospective Cohort Study

https://t.co/dnRRrtcSOB

@MeredithGunder
@SyedAAhmad5

[Society of Surgical Oncology @SocSurgOnc]

The SSO is accepting applications for 2026 committee openings!

- Be an active SSO member.
- Commit your time + expertise.
- Attend the Joint Committee Conference held at the SSO Annual Meeting.

Keep an eye on your inbox for the link to apply! Learn more: https://t.co/cekJZ5v6e9

[Julie Hallet @HalletJulie]

Specialized HPB anesthesia teams could ⬆️outcomes
The pushback? ⚠️“They will lose volume (experience) in other surgeries”

We put it to the test👀👇🏻
Bottom line: they do not

💭Time to stop hesitating? Make specialized HPB anesthesia happen

https://t.co/Zd58CJX24m @BJSurgery

[Anthony Villano, MD @AMVillanoMD]

Our new Surg Onc text for students is finally in print and available! Grateful to @JeffreyFarma for the opportunity and huge appreciation for all the co-authors (too many to tag, you all rock🙏🏻). Check it out on the Amazon store 📚 @AAMCtoday @SocSurgOnc @AmBdSurg

[NEJM @NEJM]

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research Summary: https://t.co/IM8wwyIAad

[Manish S Bhandare @Manishbhandare4]

Intra operative revision of +ve margin ⬆️ survival in gastric & GE junction adenoCa

✔️ R0 resection remains crucial
✔️ Even in locally advanced cases, margin revision improves outcomes—esp. in N0/N1 disease

🔗 https://t.co/I0gp4YRfF9

@Shrikhande_SV @JournalofGISurg @timpawlik

[Annals of Surgery @AnnalsofSurgery]

Serum EV-MDM2 DNA was significantly higher in liposarcoma patients vs controls and dropped after resection—suggesting its promise as a recurrence biomarker.
https://t.co/c5O2KwVnVM

[Julie Hallet @HalletJulie]

Stable OR teams contribute to better outcomes🤝✨

Each additional case done by same anesthesiologist-surgeon team 👉 ⬇️ major morbidity

🔓‼Opportunity is knocking: ⬆️outcomes by re-organizing teams

How to do it?

🆕📝@JAMASurgery https://t.co/FWQ7uUPYfC

[Dr Amol Akhade @SuyogCancer]

Infact we have 6 regimens now in advanced HCC .
Nivo plus IPI data ( checkmate 9DW ) updated for comparison @OncoAlert

[Dr. Nina Niu Sanford @NiuSanford]

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!)

PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

[Society of Surgical Oncology @SocSurgOnc]

May is Melanoma Cancer awareness month #SSOCommunity #Melanoma #SurgicalOncologists

[Annals of Surgical Oncology @AnnSurgOncol]

April Issue: Defining Textbook Outcomes for Minimally Invasive Surgical Resection of Small Gastrointestinal #StromalTumors (GIST) of the Stomach @GrahamSpurzem @JasonSicklick @chandrajitraut

https://t.co/OhtPhA9oRd

@MeredithGunder
@SyedAAhmad5